Tags

Type your tag names separated by a space and hit enter

Effect of ellagic acid on cyclosporine A-induced oxidative damage in the liver of rats.

Abstract

Cyclosporine A (CsA) is an immunosuppressor, which is most frequently used in the transplant surgery and in the treatment of autoimmune diseases. It has been shown that CsA is able to generate reactive oxygen species and lipid peroxidation, which are directly involved in the CsA nephrotoxicity, hepatotoxicity and cardiotoxicity. This study was undertaken to investigate the protective effect of ellagic acid (EA), a polyphenolic compound against CsA-induced liver injury in male Wistar rats. In this study, CsA was administered orally (25 mg/kg body weight) for 21 days to induce toxicity. EA was administered orally (12.5, 25 and 50 mg/kg body weight) for 21 days along with oral administration of CsA. CsA-induced liver damage was evidenced by increased activities of serum hepatic enzymes namely aspartate transaminase, alanine transaminase, alkaline phosphatase and lactate dehydrogenase with a significant elevation of lipid peroxidation markers such as thiobarbituric acid reactive substances (TBARS) and hydroperoxides in the liver. The levels of enzymic antioxidants such as superoxide dismutase, catalase and glutathione-S-transferase and non-enzymic antioxidants (vitamin C, vitamin E and reduced glutathione) were also decreased in CsA-treated rats. Administrations of EA at 50 mg/kg body weight significantly decreased the activities of hepatic marker enzymes compared with other doses of EA (12.5, 25 mg/kg body weight). In addition, the levels of TBARS and hydroperoxides were significantly decreased and the levels of enzymic and non-enzymic antioxidants significant increased on treatment with EA in the liver. The biochemical observation was supplemented by histopathologic examination of liver section. The results of this study indicate that EA might play an important role in protecting CsA-induced oxidative damage in the liver.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar 608002, Tamilnadu, India. paribalaji@gmail.com

    Source

    Fundamental & clinical pharmacology 22:4 2008 Aug pg 395-401

    MeSH

    Alanine Transaminase
    Alkaline Phosphatase
    Animals
    Antioxidants
    Aspartate Aminotransferases
    Catalase
    Chemical and Drug Induced Liver Injury
    Cyclosporine
    Drug Antagonism
    Ellagic Acid
    Glutathione Transferase
    Immunosuppressive Agents
    L-Lactate Dehydrogenase
    Lipid Peroxidation
    Liver
    Liver Diseases
    Male
    Oxidative Stress
    Rats
    Rats, Wistar
    Superoxide Dismutase
    Thiobarbituric Acid Reactive Substances

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    18705750

    Citation

    Pari, Leelavinothan, and Ramasamy Sivasankari. "Effect of Ellagic Acid On Cyclosporine A-induced Oxidative Damage in the Liver of Rats." Fundamental & Clinical Pharmacology, vol. 22, no. 4, 2008, pp. 395-401.
    Pari L, Sivasankari R. Effect of ellagic acid on cyclosporine A-induced oxidative damage in the liver of rats. Fundam Clin Pharmacol. 2008;22(4):395-401.
    Pari, L., & Sivasankari, R. (2008). Effect of ellagic acid on cyclosporine A-induced oxidative damage in the liver of rats. Fundamental & Clinical Pharmacology, 22(4), pp. 395-401. doi:10.1111/j.1472-8206.2008.00609.x.
    Pari L, Sivasankari R. Effect of Ellagic Acid On Cyclosporine A-induced Oxidative Damage in the Liver of Rats. Fundam Clin Pharmacol. 2008;22(4):395-401. PubMed PMID: 18705750.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Effect of ellagic acid on cyclosporine A-induced oxidative damage in the liver of rats. AU - Pari,Leelavinothan, AU - Sivasankari,Ramasamy, PY - 2008/8/19/pubmed PY - 2008/11/15/medline PY - 2008/8/19/entrez SP - 395 EP - 401 JF - Fundamental & clinical pharmacology JO - Fundam Clin Pharmacol VL - 22 IS - 4 N2 - Cyclosporine A (CsA) is an immunosuppressor, which is most frequently used in the transplant surgery and in the treatment of autoimmune diseases. It has been shown that CsA is able to generate reactive oxygen species and lipid peroxidation, which are directly involved in the CsA nephrotoxicity, hepatotoxicity and cardiotoxicity. This study was undertaken to investigate the protective effect of ellagic acid (EA), a polyphenolic compound against CsA-induced liver injury in male Wistar rats. In this study, CsA was administered orally (25 mg/kg body weight) for 21 days to induce toxicity. EA was administered orally (12.5, 25 and 50 mg/kg body weight) for 21 days along with oral administration of CsA. CsA-induced liver damage was evidenced by increased activities of serum hepatic enzymes namely aspartate transaminase, alanine transaminase, alkaline phosphatase and lactate dehydrogenase with a significant elevation of lipid peroxidation markers such as thiobarbituric acid reactive substances (TBARS) and hydroperoxides in the liver. The levels of enzymic antioxidants such as superoxide dismutase, catalase and glutathione-S-transferase and non-enzymic antioxidants (vitamin C, vitamin E and reduced glutathione) were also decreased in CsA-treated rats. Administrations of EA at 50 mg/kg body weight significantly decreased the activities of hepatic marker enzymes compared with other doses of EA (12.5, 25 mg/kg body weight). In addition, the levels of TBARS and hydroperoxides were significantly decreased and the levels of enzymic and non-enzymic antioxidants significant increased on treatment with EA in the liver. The biochemical observation was supplemented by histopathologic examination of liver section. The results of this study indicate that EA might play an important role in protecting CsA-induced oxidative damage in the liver. SN - 1472-8206 UR - https://www.unboundmedicine.com/medline/citation/18705750/Effect_of_ellagic_acid_on_cyclosporine_A_induced_oxidative_damage_in_the_liver_of_rats_ L2 - https://doi.org/10.1111/j.1472-8206.2008.00609.x DB - PRIME DP - Unbound Medicine ER -